Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Q Lacy

Showing results (71-80 of 142) with videos related to

Pageof 15
Sort By:
Leukemia|January 15, 2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisP Kapoor, S V Rajkumar, A Dispenzieri, et al.
British Journal of Haematology|April 8, 1998
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantationA Palmas, A Tefferi, J L Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Blood Cancer Journal|December 17, 2016
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent eraR Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Leukemia|October 29, 2011
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, et al.
Leukemia|March 13, 2014
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myelomaW I Gonsalves, S V Rajkumar, V Gupta, et al.
Pageof 15

Showing results (71-80 of 142) with videos related to

Sort By:
Pageof 15
Leukemia|January 15, 2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisP Kapoor, S V Rajkumar, A Dispenzieri, et al.
British Journal of Haematology|April 8, 1998
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantationA Palmas, A Tefferi, J L Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Blood Cancer Journal|December 17, 2016
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent eraR Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Leukemia|October 29, 2011
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, et al.
Leukemia|March 13, 2014
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myelomaW I Gonsalves, S V Rajkumar, V Gupta, et al.
Pageof 15